Skip to content
2000
  1. Home
  2. A-Z Publications
  3. The International Journal of Gastroenterology and Hepatology Diseases
  4. Volume 1, Issue 2
  5. Article
Volume 1, Issue 2
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

The International Journal of Gastroenterology and Hepatology Diseases starts with a new section on drug induced liver injury (DILI) and herb induced liver injury (HILI), and as its section editor, I would appreciate receiving submissions from potential authors. Closely connected with these forms of liver injury are topics of pathophysiology, clinical features, risk factors on the side of patients as well as drugs or herbs, diagnostic approaches including causality assessment using the updated RUCAM (Roussel Uclaf Causality Assessment Method), and treatment modalities that help reduce risks of acute liver failure, liver transplantation, and lethal outcome. In conclusion, this new section on DILI and HILI will hope fully provide additional insights into the issues related to DILI and HILI.

© 2022 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/2666290602666221125161151
2022-12-23
2025-03-02

  • From This Site

    /content/journals/ijghd/10.2174/2666290602666221125161151
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/ijghd/1/2/IJGHD-1-2-E251122211281.html?itemId=/content/journals/ijghd/10.2174/2666290602666221125161151&mimeType=html&fmt=ahah

References

  1. TeschkeR. Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): Cascade of events, clinical aspects, and pharmacotherapy options.Expert Opin. Pharmacother.201819877979310.1080/14656566.2018.1465929 29708448
     [Google Scholar]
  2. TeschkeR. Alcoholic liver disease: Alcohol metabolism, cascade of molecular mechanisms, cellular targets, and clinical aspects.Biomedicines20186410610.3390/biomedicines6040106 30424581
     [Google Scholar]
  3. JiangY. ZhangT. KusumanchiP. HanS. YangZ. LiangpunsakulS. Alcohol metabolizing enzymes, microsomal ethanol oxidizing system, cytochrome P450 2E1, catalase, and aldehyde dehydrogenase in alcohol-associated liver disease.Biomedicines2020835010.3390/biomedicines8030050 32143280
     [Google Scholar]
  4. TeschkeR. NeumanM.G. LiangpunsakulS. SeitzH.K. Alcoholic liver disease and the co-triggering role of MEOS with its CYP 2E1 catalytic cycle and ROS.Arch. Gastroenterol. Res.20212925
     [Google Scholar]
  5. ParasherA. AggrawalA. Prognosis and treatment options in cases of acute liver failure caused by mushroom poisoning due to Amanita phalloides.Int. J. Adv. Med.20207587588010.18203/2349‑3933.ijam20201629
     [Google Scholar]
  6. TeschkeR. Liver injury by carbon tetrachloride intoxication in 16 patients treated with forced ventilation to accelerate toxin removal via the lungs: A clinical report.Toxics2018622510.3390/toxics6020025 29702608
     [Google Scholar]
  7. TeschkeR. Intoxications by aliphatic halogenated hydrocarbons: Hepatotoxic risks for patients and clinical issues including role of CO2-induced hyperventilation as therapy option.J. Clin. Exp. Tox.201822529
     [Google Scholar]
  8. TeschkeR. Aliphatic halogenated hydrocarbons: Liver injury in 60 patients.J. Clin. Transl. Hepatol.20186435036110.14218/JCTH.2018.00040 30637211
     [Google Scholar]
  9. KimJ.W. ParkS. LimC.W. LeeK. KimB. The role of air pollutants in initiating liver disease.Toxicol. Res.2014302657010.5487/TR.2014.30.2.065 25071914
     [Google Scholar]
  10. TeschkeR. Aluminum, arsenic, beryllium, cadmium, chromium, cobalt, copper, iron, lead, mercury, molybdenum, nickel, platinum, thallium, titanium, vanadium, and zinc: Molecular aspects in experimental liver injury.Int. J. Mol. Sci.202223201221310.3390/ijms232012213 36293069
     [Google Scholar]
  11. KeL. LuC. ShenR. LuT. MaB. HuaY. Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010-2019).Front. Pharmacol.20201184210.3389/fphar.2020.00842 32581801
     [Google Scholar]
  12. DananG. BenichouC. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries.J. Clin. Epidemiol.199346111323133010.1016/0895‑4356(93)90101‑6 8229110
     [Google Scholar]
  13. BenichouC. DananG. FlahaultA. Causality assessment of adverse reactions to drugs-I. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge.J. Clin. Epidemiol.199346111331133610.1016/0895‑4356(93)90102‑7 8229111
     [Google Scholar]
  14. DananG. TeschkeR. RUCAM in drug and herb induced liver injury: The update.Int. J. Mol. Sci.20161711410.3390/ijms17010014 26712744
     [Google Scholar]
  15. RealM. BarnhillM.S. HigleyC. RosenbergJ. LewisJ.H. Drug-induced liver injury: Highlights of the recent literature.Drug Saf.201942336538710.1007/s40264‑018‑0743‑2 30343418
     [Google Scholar]
  16. RosenbergJ.J. HigleyC. ShabazS. LewisJ.H. Selected highlights and controversies of drug-induced liver injury from the recent literature.World J. Gastroenterol. Hepatol. Endosc. Res.20201116
     [Google Scholar]
  17. ClintonJ.W. KiparizoskaS. AggarwalS. WooS. DavisW. LewisJ.H. Drug-induced liver injury: Highlights and controversies in the recent literature.Drug Saf.202144111125114910.1007/s40264‑021‑01109‑4 34533782
     [Google Scholar]
  18. TeschkeR. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.Expert Opin. Drug Metab. Toxicol.2018141111910.1080/17425255.2018.1539077 30354694
     [Google Scholar]
  19. TeschkeR. DananG. Idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI): Diagnostic algorithm based on the quantitative Roussel Uclaf Causality Assessment Method (RUCAM).Diagnostics (Basel)202111345810.3390/diagnostics11030458 33800917
     [Google Scholar]
  20. TeschkeR. DananG. Worldwide use of RUCAM for causality assessment in 81, 856 idiosyncratic DILI and 14,029 HILI cases published 1993-mid 2020: A comprehensive analysis.Medicines20207106210.3390/medicines7100062 33003400
     [Google Scholar]
  21. TeschkeR. EickhoffA. SchulzeJ. DananG. Herb-induced liver injury (HILI) with 12, 068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): An overview.Transl. Gastroenterol. Hepatol.202165110.21037/tgh‑20‑149 34423172
     [Google Scholar]
  22. TeschkeR. ZhuY. JingJ. Herb induced liver injury (HILI) in the Asian region and current role of RUCAM for causality assessment in 11,160 published cases: Analysis and outlook.J. Clin. Transl. Hepatol.2020820021410.14218/JCTH.2020.00009 32832401
     [Google Scholar]
  23. UetrechtJ. Mechanistic studies of idiosyncratic DILI: Clinical implications.Front. Pharmacol.201910837
     [Google Scholar]
  24. JeeA. SernoskieS.C. UetrechtJ. Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges.Int. J. Mol. Sci.2021226295410.3390/ijms22062954 33799477
     [Google Scholar]
  25. TeschkeR. UetrechtJ. Mechanism of idiosyncratic drug induced liver injury (DILI): Unresolved basic issues.Ann. Transl. Med.20219730
     [Google Scholar]
  26. UetrechtJ. Are drugs containing a carboxylic acid functional group associated with a significant risk of idiosyncratic drug reactions.J. Modern Med. Chem.202081566410.12970/2308‑8044.2020.08.07
     [Google Scholar]
  27. TeschkeR. DananG. Liver injury by drugs metabolized via cytochrome P450.J. JMMC202081939810.12970/2308‑8044.2020.08.12
     [Google Scholar]
  28. TeschkeR. DananG. Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors, and lipophilicity: Highlights and controversies.Int. J. Mol. Sci.2021227344110.3390/ijms22073441 33810530
     [Google Scholar]
  29. WengZ. WangK. LiH. ShiQ. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.Oncotarget2015619170311703810.18632/oncotarget.4400 26220713
     [Google Scholar]
  30. TeschkeR. SchulzeJ. EickhoffA. DananG. Drug induced liver injury: Can biomarkers assist RUCAM in causality assessment?Int. J. Mol. Sci.20171880310.3390/ijms18040803
     [Google Scholar]
  31. MeunierL. LarreyD. Drug-induced liver injury: Biomarkers, requirements, candidates, and validation.Front. Pharmacol.201910148210.3389/fphar.2019.01482 31920666
     [Google Scholar]
  32. TeschkeR. EickhoffA. BrownA.C. NeumanM.G. SchulzeJ. Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: Tricky dilemma after EMA correctly and officially retracted letter of support.Int. J. Mol. Sci.201921121210.3390/ijms21010212 31892250
     [Google Scholar]
  33. TeschkeR. Editorial. DILI, HILI, RUCAM algorithm, and AI, the Artificial Intelligence: Provocative issues, progress, and proposals.Arch. Gastroenterol. Res.20201411
     [Google Scholar]
  34. ScalfaroE. StreefkerkH.J. MerzM. MeierC. LewisD. Preliminary results of a novel algorithmic method aiming to support initial causality assessment of routine pharmacovigilance case reports for medication-induced liver injury: The PV-RUCAM.Drug Saf.201740871572710.1007/s40264‑017‑0541‑2 28508325
     [Google Scholar]
  35. BjörnssonE. OlssonR. Outcome and prognostic markers in severe drug-induced liver disease.Hepatology200542248148910.1002/hep.20800 16025496
     [Google Scholar]
  36. Kullak-UblickG.A. MerzM. GriffelL. KaplowitzN. WatkinsP.B. Liver safety assessment in special populations (hepatitis B, C, and oncology trials).Drug Saf.201437S1576210.1007/s40264‑014‑0186‑3 25352328
     [Google Scholar]
  37. Muhović D.; Bojović J.; Bulatović A.; Vukčević B.; Ratković M.; Lazović R.; Smolović B. First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19.Liver Int.20204081901190510.1111/liv.14516 32478465
     [Google Scholar]
  38. ChenF. ChenW. ChenJ. XuD. XieW. WangX. XieY. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases.Ann. Hepatol.20212110026710.1016/j.aohep.2020.09.011 33053426
     [Google Scholar]
  39. DelgadoA. StewartS. UrrozM. RodríguezA. BorobiaA.M. Akatbach-BousaidI. González-MuñozM. RamírezE. Characterisation of drug-induced liver injury in patients with COVID-19 detected by a proactive pharmacovigilance program from laboratory signals.J. Clin. Med.20211019443210.3390/jcm10194432 34640458
     [Google Scholar]
  40. JothimaniD. VijM. SanglodkarU. PatilV. SachanD. NarasimhanG. KaliamoorthyI. RelaM. Severe jaundice in a COVID-19 patient-virus or drug?J. Clin. Exp. Hepatol.202111340740810.1016/j.jceh.2021.02.006 33654344
     [Google Scholar]
  41. KumarP. KulkarniA. SharmaM. RaoP.N. ReddyD.N. Letter to the editor. Favipiravir-induced liver injury in patients with coronavirus disease 2019.J. Clin. Transl. Hepatol.20219227627810.1111/liv.14516 34007812
     [Google Scholar]
  42. YamazakiS. SuzukiT. SayamaM. NakadaT. IgariH. IshiiI. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.J. Infect. Chemother.202127239039210.1016/j.jiac.2020.12.021 33402301
     [Google Scholar]
  43. TeschkeR. DananG. Editorial. DILI cases in registries and databases: An analysis of quality.J. Gastroenterol. Hepatol.202211e01062119245610.2174/2666290601666210325091553
     [Google Scholar]
  44. ShenT. LiuY. ShangJ. XieQ. LiJ. YanM. XuJ. NiuJ. LiuJ. WatkinsP.B. AithalG.P. AndradeR.J. DouX. YaoL. LvF. WangQ. LiY. ZhouX. ZhangY. ZongP. WanB. ZouZ. YangD. NieY. LiD. WangY. HanX. ZhuangH. MaoY. ChenC. Incidence and etiology of drug-induced liver injury in Mainland China.Gastroenterology2019156822302241.e1110.1053/j.gastro.2019.02.002 30742832
     [Google Scholar]
  45. YangM. LiZ. DouD. Letter to the editor. Can retrospective studies confirm causes of drug-induced liver injury? RE: Incidence and etiology of drug-induced liver injury in Mainland China.Gastroenterology201915751436143710.1053/j.gastro.2019.03.078 31442432
     [Google Scholar]
  46. DevarbhaviH. BjörnssonE.S. Letter to the editor. RE: Incidence and etiology of drug-induced liver injury in Mainland China.Gastroenterology201915751437143810.1053/j.gastro.2019.06.045 31442436
     [Google Scholar]
  47. CongW. XinQ. GaoY. Letter to the editor. RE: Incidence and etiology of drug-induced liver injury in Mainland China.Gastroenterology201915751438143910.1053/j.gastro.2019.05.076
     [Google Scholar]
  48. ShenT. MaoY. ChenC. Reply to letters of the editor on: Incidence and etiology of drug-induced liver injury in Mainland China.Gastroenterology201915719391940
     [Google Scholar]
  49. BjörnssonE.S. Hepatotoxicity by drugs: The most common implicated agents.Andrade. Int. J. Mol Sci.20161722410.3390/ijms17020224
     [Google Scholar]
  50. BjörnssonE.S. HoofnagleJ.H. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports.Hepatology201663259060310.1002/hep.28323 26517184
     [Google Scholar]
  51. TeschkeR. DananG. The LiverTox paradox-gaps between promised data and reality check.Diagnostics20211110175410.3390/diagnostics11101754 34679453
     [Google Scholar]
  52. DananG. TeschkeR. Roussel Uclaf causality assessment method for drug-induced liver injury: Present and future.Front. Pharmacol.20191085310.3389/fphar.2019.00853
     [Google Scholar]
  53. DananG. TeschkeR. Major pitfalls call for caution and proper validation.Hepatology202276e27
     [Google Scholar]
  54. LiM. LuoQ. TaoY. SunX. LiuC. Pharmacotherapies for drug-induced liver injury: A current literature review.Front. Pharmacol.20221280624910.3389/fphar.2021.806249 35069218
     [Google Scholar]
  55. HuP.F. XieW.F. Corticosteroid therapy in drug‐induced liver injury: Pros and cons.J. Dig. Dis.201920312212610.1111/1751‑2980.12697 30582289
     [Google Scholar]
  56. BjörnssonE.S. VucicV. StirnimannG. Robles-DíazM. Role of corticosteroids in drug-induced liver injury - A systematic review.Front. Pharmacol.20221382072410.3389/fphar.2022.820724 35222034
     [Google Scholar]
  57. ZoubekM.E. Pinazo-BanderaJ. Ortega-AlonsoA. HernándezN. CrespoJ. ContrerasF. Medina-CálizI. Sanabria-CabreraJ. Sanjuan-JiménezR. González-JiménezA. García-CortésM. LucenaM.I. AndradeR.J. Robles-DíazM. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review.United European Gastroenterol. J.20197682583710.1177/2050640619840147 31316787
     [Google Scholar]
  58. QuanN.V. DangXuan T.; Teschke, R. Potential hepatotoxins found in herbal medicinal products: A systematic review.Int. J. Mol. Sci.20202114501110.3390/ijms21145011 32708570
     [Google Scholar]
  59. FrenzelC. TeschkeR. Herbal hepatotoxicity: Clinical characteristics and listing compilation.Int. J. Mol. Sci.201617558810.3390/ijms17050588 27128912
     [Google Scholar]
  60. BrewerC. ChenT. Hepatotoxicity of herbal supplements mediated by modulation of cytochrome P450.Int. J. Mol. Sci.20171811235310.3390/ijms18112353 29117101
     [Google Scholar]
  61. TeschkeR. VongdalaN. QuanN.V. QuyT.N. XuanT.D. Toxifying 1, 2-unsaturated pyrrolizidine alkaloids causing human hepatic sinusoidal obstruction syndrome. SI: molecular toxicology.Int. J. Mol. Sci.2021221041910.3390/ijms221910419 34638760
     [Google Scholar]
  62. LinG. WangJ.Y. LiN. LiM. GaoH. JiY. ZhangF. WangH. ZhouY. YeY. XuH.X. ZhengJ. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.J. Hepatol.201154466667310.1016/j.jhep.2010.07.031 21146894
     [Google Scholar]
  63. GaoH. LiN. WangJ.Y. ZhangS.C. LinG. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.J. Dig. Dis.2012131333910.1111/j.1751‑2980.2011.00552.x 22188914
     [Google Scholar]
  64. WangJ.Y. GaoH. Tusanqi and hepatic sinusoidal obstruction syndrome.J. Dig. Dis.201415310510710.1111/1751‑2980.12112 24528632
     [Google Scholar]
  65. WangR. QiX. YoshidaE.M. Méndez-SánchezN. TeschkeR. SunM. LiuX. SuC. DengJ. DengH. HouF. GuoX. Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: A systematic review.Expert Rev. Gastroenterol. Hepatol.201812442543410.1080/17474124.2018.1427581 29323538
     [Google Scholar]
  66. MelchartD. HagerS. AlbrechtS. DaiJ. WeidenhammerW. TeschkeR. Herbal traditional chinese medicine and suspected liver injury: A prospective study.World J. Hepatol.20179291141115710.4254/wjh.v9.i29.1141 29085558
     [Google Scholar]
/content/journals/ijghd/10.2174/2666290602666221125161151
Loading

  • Article Type:     Editorial
Keyword(s): COVID-19; DILI; drug induced liver injury; herb induced liver injury; HILI; immune checkpoint inhibitors; roussel uclaf causality assessment method; RUCAM

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test